Resistance to osimertinib remains a major challenge in epidermal growth factor receptor-mutant non-small-cell lung cancer (NSCLC), with approximately 40 to 50% of cases lacking identifiable genotypic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback